

Rimegepant: Adis Evaluation

Clinical Considerations

- Small molecule CGRP receptor antagonist
- Available as an orally disintegrating tablet formulation
- Relieves pain and the most bothersome symptom when taken as needed for the acute treatment of migraine
- Reduces migraine frequency when taken every other day for the preventive treatment of migraine
- Generally well tolerated

Plain Language Summary

Background and rationale

- Migraine is a type of headache that causes severe throbbing pain, usually on one side of the head. Bothersome symptoms that may occur during a migraine include nausea, vomiting and sensitivity to light and sound
- Medications for migraine are aimed at stopping symptoms (acute treatment) and/or reducing the frequency of future attacks (preventive treatment)
- Calcitonin gene-related peptide (CGRP) is a protein that is released during migraine attacks, causing inflammation and activation of other pathophysiological processes responsible for pain
- Rimegepant [Nurtec® ODT (USA); Vydura® (EU)] is an oral medication that works by blocking the CGRP receptors. A convenient quick-dissolve tablet formulation is available that can be placed on or under the tongue and swallowed without water

Clinical findings

- Rimegepant relieves pain and bothersome symptoms when taken as needed for a single migraine attack, and reduces the number of migraine days per month when taken every other day to help prevent migraine
- Rimegepant is generally well tolerated

Conclusion

As the first medication approved to both treat acute migraine attacks and help prevent future attacks, rimegepant represents a useful treatment option for patients with migraine

This plain language summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2023.